136 related articles for article (PubMed ID: 16868724)
1. Key factors in experimental mouse hematopoietic stem cell transplantation.
Nevozhay D; Opolski A
Arch Immunol Ther Exp (Warsz); 2006; 54(4):253-69. PubMed ID: 16868724
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
5. Hurdles to the induction of tolerogenic mixed chimerism.
Pilat N; Klaus C; Schwaiger E; Wekerle T
Transplantation; 2009 May; 87(9 Suppl):S79-84. PubMed ID: 19424016
[TBL] [Abstract][Full Text] [Related]
6. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
7. Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.
Ophir E; Reisner Y
Int Immunopharmacol; 2009 Jun; 9(6):694-700. PubMed ID: 19150657
[TBL] [Abstract][Full Text] [Related]
8. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
[TBL] [Abstract][Full Text] [Related]
9. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
[TBL] [Abstract][Full Text] [Related]
10. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
12. In utero hematopoietic stem cell transplantation: progress toward clinical application.
Merianos D; Heaton T; Flake AW
Biol Blood Marrow Transplant; 2008 Jul; 14(7):729-40. PubMed ID: 18541191
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European group for Blood and Marrow Transplantation (EBMT).
Bacigalupo A
Bone Marrow Transplant; 2000 Apr; 25(8):803-5. PubMed ID: 10808199
[TBL] [Abstract][Full Text] [Related]
14. The A-B-C of haematopoietic stem cell transplantation.
Rafeah NT; Fadilah SA
Med J Malaysia; 2009 Mar; 64(1):94-100; quiz 101. PubMed ID: 19852335
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral tolerance.
Wekerle T; Blaha P; Koporc Z; Bigenzahn S; Pusch M; Muehlbacher F
Transplantation; 2003 May; 75(9 Suppl):21S-25S. PubMed ID: 12819486
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
17. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
18. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation.
Wright-Kanuth MS; Smith LA
Clin Lab Sci; 2001; 14(2):112-7. PubMed ID: 15625984
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
Saito TI; Rubio MT; Sykes M
Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
